Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
They are in the program as of Oct 23
LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life Sciences - New York, NY (United States)
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
No one seems to think it a coincidence Anavex got a slot for LB at CTAD after BIIB will go to the FDA advisory meeting to discuss the BLA within hours of each other with their joke of a candidate?
Last year it was BIIB lying to steal Anavex thunder.........
This year......
What’s the time difference?
And if BIIB gets their candidate approved next month?
COVID-19 Might Increase Risk of Memory Loss and Cognitive Decline
https://www.discovermagazine.com/health/how-covid-19-might-increase-risk-of-memory-loss-and-cognitive-decline
If A-273 does get approved for any indication, what’s the chances of doctors prescribing a-273 for the above?
What other treatment plans is there for neurological damage covid leaves behind.
Another dot connected. How long ago was it that the topic of the day on the board was the gut?
https://www.yahoo.com/news/researchers-study-between-gut-health-213618194.html
When’s the cover by date for shorts?
CDC Taps Alzheimer’s Association to Lead National Effort to Slash Dementia Risk
https://alzheimersnewstoday.com/2020/09/28/cdc-taps-alzheimers-association-to-lead-national-effort-to-slash-dementia-risk/
Guess someone could call HR, find out and report back.
Not sure if this one is being tracked:
Protein Misfolding Drug Discovery Summit
When:
Oct. 27 2020
Where:
The Westin Copley Place
10 Huntington Ave Boston, MA 02116
Speaking:
Christopher Missling President and CEO Anavex Life Sciences
https://boston.eventful.com/events/protein-misfolding-drug-di-/E0-001-133314844-0@2020102709
Or paid
What’s this for? Most people here were owned stock ALREADY when this happened. What’s next, the high of $15 soon after the up listing?
Economy won’t recover in Hawaii as we still have stay at home till May 31.
Doesn’t mean tourists aren’t showing up and disregarding the 14 day quarantine.
Luckily, I’m an essential worker outside of the food and tourist industry
THAT is just as much a false statement as saying Eisai hired him to help with the collaboration between Eisai and Anavex.
BOTTOM line, no one knows so best bet is to just keep quiet and reflect 10 years from now.
Just shows how much confidence they have in their smoke and mirror trick they pulled late last year.
Berkshire bought 648,000 shares worth $192M of BIIB. To think how much more he would have profited had he invested in AVXL is crazy
We aren’t even close to what the pps should be. $10-$15 is more where it should be trading.
The street is starting to take notice, FINALLY.
Between Anavex and BIIB, which would be the more riskier pick for a successful ALZ treatment.
Disappointing to see that the DIAN trial looking into the efficacy of gantenerumab and solanezumab to slow familial #Alzheimer's disease did not meet its primary endpoints
https://t.co/b8BCj1xPF0
That wouldn’t happen to be the p3 trial that they stopped and threw in the towel is it? Then they did a newly discovered equation and walla......they are now trying to get back in the game saying the patients DID improve.... look at my new cherry picked data it doesn’t LIE........
Nice post Jimmy. Finally someone that took what I was thinking about valuation of companies and put it all on paper.
If top line for Rett, PDD is positive you can bet ALZ patients as well as Drs will want to see if they or their patients qualify for the P2/3 trial
Cuttlefish, my favorite
“It looks as though when naturally-occurring genetic variants reduce the activity of tyrosine phosphatases then this makes Alzheimer's disease less likely to develop, suggesting drugs which have the same effect might also be protective.”
https://www.yahoo.com/news/genetic-mutations-that-may-protect-against-alzheimers-discovered-by-scientists-000149026.html
Or BIIB attempt to get back in the Alzheimer’s field
How about possibly kicking yourself years later for selling way to early
You say disappointed with the result, I say disappointed they couldn’t hammer out a license on the cheap.
Bottom line ......either/or could be correct.
NOBODY else knows besides the 2 companies.
Biogen to buy experimental Alzheimer's, Parkinson's treatment from Pfizer for $75M plus incentives
There they go again.
https://www.yahoo.com/finance/news/biogen-buy-experimental-alzheimer-apos-144544214.html
With whom he has to work with in the states to get this approved he is doing just fine. Most any other ceo would have put this co under water
Could you remind us exactly how much of said stock actually hit the market so far?
What a great observation .com
With that thought..... Apple was so close to being bankrupt that Steve actually lost his Job.
Of course.....the rest of the story is history.
Which then brings the ol saying
History repeating itself.
Anavex.... all the haters hated.....
How can a 100M cap company figure out what a 10....20....50 Billion dollar company can’t?
The rest of the story..... is history
Nice read:
https://qz.com/1748071/how-well-find-an-effective-treatment-for-alzheimers/?utm_source=YPL&yptr=yahoo
“The amyloid hypothesis has come under question as a result, and has even been outright abandoned by some researchers and leaders in the field.
This was clear at the Alzheimer’s Association International Conference (AAIC) this year, where several thought leaders used their podium to call for researchers to look beyond beta-amyloid.”
“In the center’s study, Jucker and his colleagues detected increases in Nf-L 16 years before symptoms of Alzheimer’s were present in a cohort of patients with familial Alzheimer’s disease.
Nf-L has already demonstrated success in facilitating the early detection and/or prognosis of a variety of neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, and Lewy body dementia.”
If a-273 were approved, would they need to be in a rush to approve 371 so quick?
Did NTRP receive one?
I’m content with my core amount of shares. If we go sub $2 again though, I’m definitely adding to it.
My 401K has nothing but time on its side.
Approximately 25 years to see if my little side play will spring any fruits.
AVXL as stocking stuffers.
100 share stuffers for less than $250 is a great future present for the little ones
By the time they turn 18, it’ll either be worth 0 or thousands of dollars
BIIB understands their entire cns inventory is at risk from being obsolete in a year or two. It’s a move they had to make, making up false new tests that show benefit for their failed clinical trial.
The future of BIIB is literally at risk from Anavex if A-273 gets to market.
ANAVEX TURNS CNS FIELD UPSIDE DOWN.
There. Simple, short, and to the point.
Much better RIGHT?
RIGHT!! How can you submit for approval when the trial FAILED!! No post mining!!no cherry picking data.
Imagine if Anavex had to resort to such measures.